A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease
Inflammatory Bowel Diseases · 03.10.2023 · 29 (10) · 1524-1535
DOI: 10.1093/ibd/izad080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 17.05.2023. Verfasst von Ruiqi Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Leona M. and Harry B. Helmsley Charitable Trust.
Abstract (Originalsprache)
Background
A distinctive metabolic phenotype provides the opportunity to discover noninvasive biomarkers for the diagnosis of Crohn’s disease (CD) and for differentiating it from other intestinal inflammatory diseases. The study sought to identify new biomarkers for CD diagnosis.
Methods
Serum metabolites from 68 newly diagnosed and treatment-naïve patients with CD and 56 healthy control (HC) subjects were profiled using targeted liquid chromatography-mass spectrometry. Five metabolic biomarkers were identified to distinguish patients with CD from the HC subjects and validated in a separate cohort consisting of 110 patients with CD and 90 HC subjects using a combination of univariate analysis, orthogonal partial least-squares discriminant analysis, and receiver-operating characteristic curve analysis. Differences in the 5 metabolites were evaluated among patients with CD and patients with ulcerative colitis (n = 62), intestinal tuberculosis (n = 48), and Behçet’s disease (n = 31).
Results
Among the 185 quantified metabolites, a panel of 5 (pyruvate, phenylacetylglutamine, isolithocholic acid, taurodeoxycholic acid, and glycolithocholic acid) were found to distinguish patients with CD with high accuracy from HC subjects, with an area under the curve of 0.861 (P < .001). The performance of the model in assessing clinical disease activity was comparable to that of the present biomarkers: C-reactive protein and erythrocyte sedimentation rate. The 5 metabolites were significantly different among the patients and were valuable in the differentiation between CD and other chronic intestinal inflammatory diseases.
Conclusions
The combination of 5 serum metabolite biomarkers for the diagnosis of CD has the potential to provide an accurate, noninvasive, and inexpensive alternative to conventional tests and might be valuable for the differentiation from other diagnostically challenging intestinal inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University, Nanning, China.
ORCID-Profile: Rui Feng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Leona M. and Harry B. Helmsley Charitable Trust
Zitieren
APA
Ma, R., Zhu, Y., Li, X., Hu, S., Zheng, D., Xiong, S., Xu, S., Xiang, L., Zhao, M., Tang, C., Zeng, Z., Chen, M., & Feng, R. (2023). A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease. Inflammatory Bowel Diseases, 29(10), 1524-1535. https://doi.org/10.1093/ibd/izad080
Vancouver
Ma R, Zhu Y, Li X, Hu S, Zheng D, Xiong S, et al. A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease. Inflammatory Bowel Diseases. 2023;29(10):1524-1535. doi:10.1093/ibd/izad080
BibTeX
@article{Ma2023,
author = {Ma, Ruiqi and Zhu, Yijun and Li, Xiaozhi and Hu, Shixian and Zheng, Danping and Xiong, Shanshan and Xu, Shu and Xiang, Liyuan and Zhao, Min and Tang, Ce and Zeng, Zhirong and Chen, Minhu and Feng, Rui},
title = {A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {10},
pages = {1524--1535},
doi = {10.1093/ibd/izad080}
}
EUVIMED